

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2012307404 B2**

(54) Title
Cynara scolymus extracts for the treatment of dyslipidaemia

(51) International Patent Classification(s)
A61K 36/28 (2006.01) **A61P 3/10** (2006.01)
A61P 3/00 (2006.01) **A61P 9/12** (2006.01)

(21) Application No: **2012307404** (22) Date of Filing: **2012.09.13**

(87) WIPO No: **WO13/037857**

(30) Priority Data

(31) Number	(32) Date	(33) Country
MI2011A001670	2011.09.16	IT

(43) Publication Date: **2013.03.21**

(44) Accepted Journal Date: **2017.05.25**

(71) Applicant(s)
Indena S.p.A.

(72) Inventor(s)
Bombardelli, Ezio

(74) Agent / Attorney
Golja Haines & Friend, PO BOX 1014, SOUTH PERTH, WA, 6951, AU

(56) Related Art
WO 2007/006391 A2
Bundy et al, Phytomedicine (2008),
Vol. 15, Pages 668-675
EP 0958828 A1
US 2008/0220096 A1
WO 2003/013562 A1
WO 2009/100970 A1
EP 1967199 A1
US 6162438 A



(51) International Patent Classification:

A61K 36/28 (2006.01) *A61P 9/12* (2006.01)
A61P 3/10 (2006.01) *A61P 3/00* (2006.01)

(21) International Application Number:

PCT/EP2012/067889

(22) International Filing Date:

13 September 2012 (13.09.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

MI2011A001670 16 September 2011 (16.09.2011) IT

(71) Applicant (for all designated States except US): **INDENA S.P.A.** [IT/IT]; Viale Ortles, 12, I-20139 Milano (IT).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **BOMBARDELLI, Ezio** [IT/IT]; Via Gabetta, 13, I-27027 Groppello Cairoli (pv) (IT).

(74) Agent: **MINOJA, Fabrizio**; Bianchetti Bracco Minoja S.R.L., Via Plinio, 63, I-20129 Milano (IT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: CYNARA SCOLYMUS EXTRACTS FOR THE TREATMENT OF DYSLIPIDAEMIA

(57) Abstract: The present invention relates to the preparation of Cynara scolymus leaf extracts, which are useful for the prevention and treatment of dyslipidaemia, in particular to increase HDL cholesterol in patients at cardiovascular risk. Said extracts are useful to normalise the lipid and carbohydrate balances and significantly increase the value of HDL cholesterol by favourably changing the LDL/HDL ratio, especially in post-infarction patients with drug-induced dyslipidaemia.



**CYNARA SCOLYMUS EXTRACTS FOR THE TREATMENT OF
DYSLIPIDAEMIA**

Summary of the invention

The present invention relates to the preparation of a novel extract of *Cynara scolymus* with a high content of flavonoids and sesquiterpenes, produced from the leaves of selected cultivars. The extracts of the invention increase the HDL cholesterol and are useful in the treatment of dyslipidaemia in patients at cardiovascular risk. As well as normalising the lipid and carbohydrate balance, the extracts of the invention are also useful to regulate dyspepsia and non-alcoholic liver steatosis. In particular, the extracts have provided to increase the HDL cholesterol value significantly in patients with below-average parametric values, by favourably changing the LDL/HDL ratio.

Prior art

Globe artichoke (*Cynara scolymus*) extracts are known for their choleretic, cholagogic, anti-dyspepsia and mildly cholesterol-reducing action; the cholesterol reduction is modest (not more than approx. 10%). The published studies differ in terms of quality of protocols and composition of the extracts used.

Obtaining *Cynara scolymus* extracts presents major problems of reproducibility, because the active ingredient content is not uniform from preparation to preparation. Evaluating the therapeutic activity of the extracts is therefore problematic, and comparisons with other known drugs are difficult, if not impossible. The low reproducibility of the extracts is due to a number of factors, such as the choice of the plant biomass and the conditions used in drying and in the extraction process. The production of the biomass is critical because the drying conditions, which are essential to maintain the active ingredient content, depend on the growing period of the plant.

The active components of artichoke extracts are caffeoylquinic acids, which

perform a choleretic, blood-sugar reducing and liver-protecting effect; flavonoids, which perform a hypolipaeic action associated with cholesterol synthesis, and cynaropicrin, which performs an anti-inflammatory action due to interaction with nuclear factor NFkB and TNF- α .

5 Reference to cited material or information contained in the text should not be understood as a concession that the material or information was part of the common general knowledge or was known in Australia or any other country.

Each document, reference, patent application or patent cited in this text is expressly incorporated herein in their entirety by reference, which means that it
10 should be read and considered by the reader as part of this text. That the document, reference, patent application, or patent cited in this text is not repeated in this text is merely for reasons for conciseness.

Throughout the specification and claims, unless the context requires otherwise, the word “comprise” or variations such as “comprises” or “comprising”,
15 will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

Description of the invention

It has now been found that an extract with an active ingredient content that guarantees marked, constant therapeutic activity can be obtained from the leaves of
20 selected artichoke cultivars. It has also been found that the cynaropicrin present in the extract of the invention also acts at hepatic level on the enzymes that regulate HDL biosynthesis.

Young leaves of the selected artichoke cultivar, preferably *Cynara scolymus* or *Cynara cardunculus*, preferably *Cynara scolymus*, are used to prepare the extract
25 of the invention. It is preferable to use the leaves about a month after the germination of the seeds or after transplanting the seedlings. The *Cynara* species are preferably produced using organic agriculture techniques, avoiding the use of pesticides and monitoring their absence in the growing medium, as pesticide

removal would be impossible without simultaneously prejudicing the content of active lipophilic ingredients responsible for modulating the formation of HDL lipoproteins.

5 A particularly preferred variety of artichoke is the spiny purple variety of *Cynara scolymus*. A plant biomass, easily dried at temperatures of between 60 and 100°C, preferably 80°C, is obtained from the plant, grown to a foliage height of 20 cm.

10 The selected cultivar must preferably have a 3.8% content of caffeoylquinic acids, 1.5% luteolin flavonoids and 3% cynaropicrin. After drying, the biomass is extracted by known methods, described, for example, in WO 2007/006391 and WO 2008/107183.

The invention provides extracts of the leaves of *Cynara* species varieties having a caffeoylquinic acid content of between 30 and 45%, preferably $35 \pm 2\%$, a flavonoid content of 8 to 16%, preferably
15 $12 \pm 2\%$, and a cynaropicrin content of 10 to 18%, preferably $13 \pm 2\%$.

Said extracts have demonstrated an unexpected activity in reducing total cholesterol, LDL cholesterol and blood glucose, and increasing cHDL. More specifically, the extract significantly reduces the fasting blood glucose, total cholesterol and LDL cholesterol levels by 20%, increases diuresis, thus helping to reduce the blood
20 pressure, and contributes to reducing liver steatosis.

In particular, it should be emphasised that an unexpectedly high increase in HDL cholesterol is observed in both hyperlipaemic individuals and those with below-normal HDL cholesterol resulting from statin treatment or cholesterol-lowering drugs. Modest, erratic increases in HDL cholesterol following the
25 administration of *Cynara scolymus* extracts have been reported in the literature, but without any evidence of reproducibility or consistency. In fact, these studies (Naturmed, 13, 17-24, 1998, Arzneimittel - Forschung, 50, 260-65, 2000, The Cochrane Library, 2002, Issue 3) report contradictory data of low

practical relevance.

Conversely, experimentation with the compositions of the invention indicates a reduction of approx. 20% in total cholesterol and LDL cholesterol, and a significant increase of 19% in HDL cholesterol. This increase, which was found to be constant over time on a case study of patients with total cholesterol ranging from 200 to 280 mg/dl, is not observed with known herbal preparations.

The extract of the invention has also proved effective on various parameters in patients suffering from metabolic syndrome, where normalisation of parameters such as blood glucose, lipid parameters and hypertension was observed.

The extracts of the invention will be formulated in suitable administration forms such as capsules or normal or gastroprotected tablets.

The preferred carriers are oils rich in ω -3 fatty acids which facilitate absorption of the cynaropicrin present in the extract.

According to a further aspect, the compositions of the invention may be administered in combination with other substances having a useful or complementary activity.

The compositions of the invention will be formulated according to conventional methods, such as those described in "Remington's Pharmaceutical Handbook", Mack Publishing Co., N.Y., USA. In particular, the compositions of the invention will be formulated according to conventional plant ingredient formulation techniques, which require particular care to be taken to avoid interactions with the excipients and the capsule matrices. Examples of oral formulations are tablets, dragées, soft and hard gelatin capsules, and cellulose capsules. The average dose corresponds to

100-500 mg of extract one to three times a day.

The following examples illustrate the invention in greater detail.

Example 1 - Cellulose capsules suitable to contain oils

Unit composition:

<i>Cynara scolymus</i> extract	200 mg
Glyceryl monostearate	10 mg
Linseed oil	q.s. for 800 mg
Soya lecithin	10 mg

Example 2 - Soft gelatin capsules

Unit composition:

5

<i>Cynara scolymus</i> extract	300 mg
Glyceryl monostearate	10 mg
Linseed oil	q.s. for 700 mg
Soya lecithin	10 mg

Example 3 - Tablets

Unit composition:

<i>Cynara scolymus extract</i>	200 mg
Microcrystalline cellulose	300 mg
Lactose	190 mg
Silicon dioxide	5 mg
Magnesium stearate	5 mg

CLAIMS

1. Extract of the leaves of *Cynara* species varieties having a caffeoylquinic acid content of 30 to 45%, a flavonoid content of 8 to 16% and a cynaropicrin content of 10 to 18%.
5
2. Extracts according to claim 1, wherein the caffeoylquinic acid content is $35 \pm 2\%$, the flavonoid content is $12 \pm 2\%$ and the cynaropicrin content is $13 \pm 2\%$.
10
3. Extracts according to claim 1 or 2 obtainable from young leaves of selected *Cynara scolymus* or *Cynara carduncolus* cultivars.
4. Extracts according to claim 3 obtainable from *Cynara scolymus* cultivars.
15
5. Extracts according to claim 4, wherein the cultivar is the spiny purple variety.
6. Extracts according to any one of claims 1 to 5 for use in the treatment of metabolic syndrome.
20
7. Extracts according to any one of claims 1 to 5 for use in the treatment of dyslipidaemia in patients at cardiovascular risk.
8. Pharmaceutical compositions comprising an extract according to any one of claims 1 to 5 as active ingredient, in admixture with at least one excipient or carrier.
25

9. Compositions according to claim 8, wherein the carrier is an oil comprising omega-3 unsaturated fatty acids.